Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cangene Corporation
Neuraxpharm Rebrands Spanish Subsidiary As It Focuses On European Profile
Neuraxpharm has rebranded a Spanish finished dosage form facility to mark its “full integration” within the group, as it focuses on building its profile in Europe.
European Countries Flags Four Medicines For Joint HTA Evaluation
Drugs for treating Duchenne muscular dystrophy and amyotrophic lateral sclerosis are among the products that the European cross-country coalition BeNeLuxA thinks would be suitable for a joint health technology evaluation.
Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
- Contract Research Organization-CRO
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cangene bioPharma, Inc.
- Chesapeake Biological Laboratories, Inc.
- Twinstrand Therapeutics Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.